Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dusigitumab, an antibody targeting IGF1 and IGF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tovetumab, an antibody targeting PDGFRA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otlertuzumab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lifastuzumab, an antibody targeting SLC34A2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fletikumab, an antibody targeting IL20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eldelumab, an antibody targeting CXCL10.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anetumab, an antibody targeting MSLN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vanucizumab, an antibody targeting ANGPT2 × VEGF-A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Indusatumab, an antibody targeting GUCY2C.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imalumab, an antibody targeting MIF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denintuzumab, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dectrekumab, an antibody targeting IL-13.